Evidence map›Paper›PMID 42824995›Full record

ArticleHemaSphere2026

One cycle of nelarabine given after induction is well tolerated but does not improve outcome in adults with T-cell precursor acute lymphoblastic leukemia: Outcome data from the UKALL14 randomized-controlled trial.

Clare J Rowntree, Amy A Kirkwood, Nadine Farah, Emma Lawrie, David I Marks, Andrew K McMillan, Tobias F Menne, Anthony V Moorman, Bela Patel, Pip Patrick and 5 more

Registry-linked trialAbstract read
In one paragraph

Article in HemaSphere, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01085617 (A Randomized Trial for Adults with Newly Diagnosed Acute Lymphoblastic Leukemia), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01085617 completednot on this map

A Randomized Trial for Adults with Newly Diagnosed Acute Lymphoblastic Leukemia

TypeinterventionalSponsorUniversity College, LondonRan2010 to 2025ConditionsLeukemia, Mucositis, Oral ComplicationsArmspalifermin, rituximab, cyclophosphamide, cytarabine, daunorubicin hydrochloride
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Clare J RowntreeCardiff and Vale UHB Cardiff United Kingdom.
Amy A KirkwoodCRUK and UCL Cancer Trial Centre, Cancer Institute UCL London United Kingdom.ORCID https://orcid.org/0000-0003-0133-7732
Nadine FarahUCL Cancer Institute London United Kingdom.
Emma LawrieCRUK and UCL Cancer Trial Centre, Cancer Institute UCL London United Kingdom.
David I MarksUnited Bristol Healthcare Trust Bristol United Kingdom.
Andrew K McMillanCentre for Clinical Haematology Nottingham City Hospital Nottingham United Kingdom.
Tobias F MenneNewcastle Upon Tyne Hospitals NHS Foundation Trust Newcastle upon Tyne United Kingdom.ORCID https://orcid.org/0000-0002-3289-2344
Anthony V MoormanResearch Cytogenomics Group, Translational and Clinical Research Institute Newcastle University Newcastle upon Tyne United Kingdom.
Bela PatelBarts Cancer Institute London United Kingdom.
Pip PatrickCRUK and UCL Cancer Trial Centre, Cancer Institute UCL London United Kingdom.
Paul SmithCRUK and UCL Cancer Trial Centre, Cancer Institute UCL London United Kingdom.
Krisztina Z AlapiQueen Mary University of London, Specialist Integrated Haematological Malignancy Diagnostic Service London United Kingdom.
Lingyi WangUCL Cancer Institute London United Kingdom.
Marc R MansourUCL Cancer Institute London United Kingdom.
Adele K FieldingUCL Cancer Institute London United Kingdom.ORCID https://orcid.org/0000-0002-4746-7789

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

UKALL14 (NCT01085617) T-cell arm was a phase 3, randomized-controlled trial. Adults aged 25-65 years were randomized 1:1 at entry to receive standard of care (SOC) or SOC + nelarabine 1.5 g/m

Identifiers

PMID42824995
PMCPMC13628557

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.